{"prompt": "['Product: MK-3475', '34', 'Protocol/Amendment No.: 604-09', 'Table 1', 'Adequate Organ Function Lab Values', 'System', 'Laboratory Value', 'Hematological', 'Absolute neutrophil count (ANC)', '>1,500/mcL', 'Platelets', '100,000 / mcL', 'Hemoglobin', '8 g/da', 'Renal', 'Serum creatinine OR', '<1.5 X ULN OR', 'calculated creatinine clearance (CrCI)b', '>60 mL/min for subjects with creatinine levels >1.5x ULN', '(GFR can also be used in place of', 'receiving cisplatin', 'creatinine or CrCl)', '>50 mL/min for subjects with creatinine levels >1.5 X ULN', 'receiving carboplatin', 'Hepatic', 'Serum total bilirubin', '<1.5 X ULN OR', 'Direct bilirubin >ULN for subjects with total bilirubin levels', '>1.5 X ULN', 'AST (SGOT) and ALT (SGPT)', '<2.5 X ULN', '5 X ULN for subjects with liver metastases', 'Coagulation', 'International Normalized Ratio (INR) or', '<1.5 X ULN unless the subject is receiving anticoagulant', 'Prothrombin Time (PT)', 'therapy as long as PT or INR is within therapeutic range of', 'intended use of anticoagulants', 'Abbreviations: ALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase);', 'AST (SGOT)=aspartate aminotransferase (serum glutamic oxaloacetic transaminase); GFR=glomerular filtration', 'rate; INR=International Normalized Ratio; ULN=upper limit of normal.', 'a Criterion must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion', 'within last 2 weeks.', 'b Creatinine clearance (CrCl) should be calculated per institutional standard.', 'Note: This table includes eligibility-defining laboratory value requirements for treatment; laboratory value', 'requirements should be adapted according to local regulations and guidelines for the administration of specific', 'chemotherapies.', '8. Be >18 years of age on day of signing informed consent.', '9. If female subject of childbearing potential, have a negative urine or serum pregnancy', 'test within 72 hours prior to receiving the first dose of study medication. If the urine', 'test is positive or cannot be confirmed as negative, a serum pregnancy test will be', 'required.', '10. If female and of childbearing potential, be willing to use an adequate method of', 'contraception as outlined in Section 5.7.2, starting with the first dose of study', 'medication through 120 days after the last dose of pembrolizumab or saline placebo', 'or up to 180 days after last dose of chemotherapeutic agents, whichever is later.', 'Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception', 'for the subject.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '35', 'Protocol/Amendment No.: 604-09', '11. If male and of childbearing potential, agree to use an adequate method of', 'contraception as outlined in Section 5.7.2, starting with the first dose of study', 'medication through 120 days after the last dose of pembrolizumab or saline placebo', 'or up to 180 days after last dose of chemotherapeutic agents, whichever is later.', 'Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception', 'for the subject.', '12. Have voluntarily agreed to participate by giving written informed consent/assent for', 'the trial. The subject may also provide consent/assent for Future Biomedical', 'Research. However, the subject may participate in the main trial without participating', 'in Future Biomedical Research.', '5.1.3 Subject Exclusion Criteria', 'The subject must be excluded from participating in the trial if the subject:', '1.', 'Has received prior systemic therapy for the treatment of SCLC.', 'Note: Palliative radiation therapy is allowed until 7 days prior to the first dose of trial', 'medication, provided that the radiated lesion is clinically stable and the patient is not', 'receiving steroids for at least 7 days prior to the first dose of study medication. The', 'radiated lesion must not be a thoracic lesion and must not be included as a target', 'lesion for RECIST 1.1 measurements.', '2. Is currently participating and receiving study therapy or has participated in a study of', 'an investigational agent and received study therapy or used an investigational device', 'within 4 weeks of the first dose of treatment for another health-related problem.', 'Note: Subjects who have entered the follow-up phase of an investigational trial may', 'participate as long as it has been at least 4 weeks since the last dose of the previous', 'investigational agent.', '3. Is expected to require any other form of antineoplastic therapy for SCLC, including', 'radiation therapy, while on study.', 'Note: Patients with PR or CR will be offered PCI therapy at the completion of the', '4 cycles of chemotherapy with or without pembrolizumab.', '4. Has known central nervous system (ie, brain and/or spinal cord) metastases and/or', 'carcinomatous meningitis. Subjects with brain metastases may participate only if they', 'satisfy all of the following:', 'Completed treatment (eg, whole brain radiation treatment [WBRT], stereotactic', 'radiosurgery, or equivalent) at least 14 days prior to the first dose of trial', 'treatment,', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}